Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 12707454.
- Also identified by PMC identifier 2683839.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors assessed CSF and plasma HIV-1 RNA and neuropsychological test performance (composite neuropsychological test Z score [NPZ-4]) in 25 HIV-1-infected subjects 4 and 8 weeks after beginning potent antiretroviral therapy that included a protease inhibitor. In the 14 subjects who entered the study on no antiretroviral treatment, NPZ-4 improvement was associated with decline in CSF HIV-1 RNA at both visits (p = 0.001 and p = 0.02), and those treated with zidovudine or indinavir had greater improvement in NPZ-4 at both visits compared to those treated with other drugs (p = 0.003 and p = 0.01).
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- HIV Protease Inhibitors
- HIV-1
- RNA, Viral
- Viremia